Skip to Content
Center for International Blood and Marrow Transplant Research

SC17-07d

Main Content

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy

Study #: SC17-07d

Study Status: Published

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.

Citation

Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC.

American Journal of Hematology. 2024, May 01: 99(5): 99(5):880-889. doi: 10.1002/ajh.27283. Epub 2024, Mar 19. PMCID:.

PubMed

PMID: 38504387

Abstract